Singapore markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.10-0.39 (-3.39%)
At close: 4:00PM EST

11.36 +0.26 (2.34%)
After hours: 7:59PM EST

Sign in to post a message.
  • M
    MARK
    Can’t wait for AH Monday March 1, 2021
    Looks like all performance criteria has been met:
    Form 4 filings depict all options taken meet total shares in 8K parameters!!!!!

    Target Value Of Award ($)
    3,500,000 J Kim
    1,500,000 P Kies
    1,500,000 L Humeau
    1,500,000 J Shea

    The Committee established the following performance goals and corresponding performance periods over which the performance goals must be attained, the satisfaction of which are conditions to earning the Awards.
    1. The first 20% each Award will be earned if the Company’s planned Phase 2/3 clinical trial for INO-4800, the Company’s COVID-19 vaccine candidate, is fully enrolled.
    2. An additional 25% of each Award will be earned if the Company receives more than a specified amount of non-dilutive, third- party funding for manufacturing and clinical development of INO-4800.
    3. An additional 25% of each Award will be earned if the Company completes manufacture of at least 100 million (1 mg equivalent) doses of INO-4800 and arrays and a specified number of its delivery devices.
    4. The remaining 30% of each Award will be earned if INO-4800 receives regulatory approval by the U.S. Food and Drug Administration and no more than a specified number of other COVID-19 vaccines have previously received such approval.
  • U
    Uncle
    J&J says 2 pppl had severe allergic reactions after getting Covid vaccine. 46 reports of anaphylaxis from those who received Pfizer’s vaccine and 16 cases for those who received Moderna’s, according to CDC 2/16.
    PUBLISHED FRI, FEB 26 20211:43 PM EST
    Berkeley Lovelace Jr.

    Two people suffered severe allergic reactions shortly after getting Johnson & Johnson’s Covid-19 vaccine, a J&J scientist told an FDA panel on Friday.

    J&J was first informed on Wednesday about the allergic reactions, Macaya Douoguih, head of clinical development and medical affairs for J&J’s vaccines division Janssen, told the FDA’s Vaccines and Related Biological Products Advisory Committee.

    One of the people was participating in an ongoing trial in South Africa and developed anaphylaxis, a severe and life-threatening allergic reaction, after getting the vaccine, she said. “We will continue to closely monitor for these events.”

    There were previously no reports of anaphylaxis in J&J’s clinical trial. The Centers for Disease Control and Prevention is currently monitoring for such events as states and pharmacies roll out Pfizer’s and Moderna’s vaccines.

    There have been 46 reports of anaphylaxis from those who received Pfizer’s vaccine and 16 cases for those who received Moderna’s, according to a CDC report published on Feb. 16. The agency said the occurrence of the reaction is in the range of those reported for the influenza vaccine.

    The CDC is asking health-care providers to monitor patients for 15 minutes after vaccination and 30 minutes for those who have a history of allergic reactions.

    If one has a severe allergic reaction after getting the first dose of Covid-19 vaccine, the CDC recommends that they do not get the second dose, even if the allergic reaction was not severe enough to require emergency care.
  • R
    R
    Just received massive good chills.

    If I'm reading these Form 4 SEC filings correctly then ...

    Kim, Jong Joseph just acquired 526,100 shares and disposed of none

    Shea, Jacqueline Elizabeth just acquired 172,466 shares at 11.1 and disposed of none

    Humeau, Laurent just acquired 172,466 shares at 11.1 and disposed of none

    Kies, Peter just acquired 172,466 shares at 11.1 and disposed of none

    Weiner, David B. just acquired 95,500 shares and disposed of none

    https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001055726
    EDGAR Search Results
    www.sec.gov
  • C
    CurrentRatio007
    any guess or word if DoD purchased/procured any of the huge $71 million dollar Cellectra funding order, and some of the order may be booked in 4Q ended Dec 2020 as revenue and report AH on Monday? Has Inovio been making these devices to fill this initial order in SD manufacturing plant and scale-up transfers to contract manufacturers to increase the supply/demand? DoD, JPEO-CBRND, JPL-CBRND-EB Cellectra purchases in 4Q should be subject to OPRA request??? Get Cellectra devices lined-up for potential vaccines makes some sense???
  • M
    Mike
    Why end of the day covering if shorts are so confident about a poor outcome come Monday?
    Big picture up a few dollars, down a few dollars is inconsequential. We are moving along nicely. Don't forget about our partnerships and manufacturing deals. Kaneka, Thermo-fisher (big names) to name a few. Last year on this date NVAX was $8. Stuck in a range like us $7-$14. One day boom. Don't chase. Know what you own and stay the course. We know we have pre-orders and upcoming trial completions. Everything is falling into place. #longandstrong
  • c
    cad
    Friday, February 26, 2021
    • INO Short Interest
    • (Opinion)
    Total volume = 12,260,547 (10-day average volume 16.21M). Range = (10.85, 11.85). Closing at 11.10 (-0.39, -3.39%)
    Short Interest volume = 3,205,687 (26.15% of total volume, 1 out of every 3.83 shares traded today was sold short, lowest since the 18.20% of Tuesday, September 08, 2020; and only the second time this number fell below 30% this year)
    Counterfeit Short Interest volume = 1,196,133 (37.31% of Short Interest volume, about average, but a drastic decrease compared to the last 2 days)
    1 out of every 10.25 shares (9.76%) traded today was a counterfeit, lowest since the 8.92% of Thursday, January 21.
    After Hours Ending 8:00 PM ET: 186,121 shares traded with a range of (11.05, 11.36), Last trade (at 19:59:51) was 199 shares at 11.36 (+0.26, +2.34%)
    Short Interest = 43,085,502 Settlement Date February 12, a decrease of 225,165 (-0.52%) from the 43,310,667 Settlement Date January 29 (updates approximately every 15 days, last updated February 24)
    Short Interest Ratio (Days to Cover) = 3.51 (based on today's volume)
    Short Interest Ratio (Days to Cover) = 2.66 (based on 10-day average volume)
    *As a free service for trolls and haters, I'll be giving the first thumb down on all my Daily Short Interest posts.

    • (Opinion) The sole purpose of this "Short Interest Report" is to gather in one place data collected and cross referenced from between 6 and 8 no-pay-wall websites to save some readers time. It never pretends to be anything more than that. Numbers and statistics are objective, hence I refrain from giving my personal subjective views here- that is up to the reader. A "Long' and a "Short" may very well digest the data presented here and arrive at opposite conclusions.
    Having said that, my personal, subjective, biased opinion is that the drastic drops in Short and Counterfeit volumes, as a fraction of the total volume and short interest volume reflect less confidence among Shorts and Counterfeiters that the share price will decrease after Monday's Earnings Call. One again, I'm not qualified, nor licensed, nor certified to give investment advice. And there is no "Money Back Guarantee".
  • D
    Dana
    Where is the news about the Phase II in China. According to the National Medical Products Administration website regarding clinical trials in China, INO finished dosing Phase II participants at the end of January. The website also says they are starting Phase III in March. How is it that Inovio is not providing investors with information about how these trails are progressing.
  • U
    Uncle
    H.C. Wainwright analyst Ram Selvaraju notes that the Ghanaian trial is the first West African study of Lassa fever. Moreover, INO-4500 notches another first; it is the only Lassa fever vaccine candidate to enter a human study.

    “We believe an ideal dosing regimen could be selected from the Phase 1b study and advanced into a Phase 2 trial in West Africa,” the 5-star analyst said. “Positive Phase 2 data may allow INO-4500 to be stockpiled for emergency use, in our view. Importantly, Inovio’s DNA medicine platform has produced and advanced multiple vaccine candidates for infectious diseases into human trials, including the COVID-19 vaccine candidate INO-4800, which provide the company with multiple shots on goal in the vaccine space.”

    For now, however, Selvaraju remains on the sidelines with a Neutral (i.e. Hold) rating. Citing “market valuation and volatility,” the analyst refrains from providing a price target. (To watch Selvaraju’s track record, click here)

    In contrast, on where the share price is heading, the rest of the Street takes a decidedly positive stance; at $18.25, the average price target implies gains of ~59% over the next 12 months. Based on 2 Buys and 3 Holds, the stock currently has a Moderate Buy consensus rating.

    220 18- to 50-year-old participants are expected to enroll in the program, who will receive two vaccinations 28 days apart with either 1.0 mg or 2.0 mg of INO-4500.

    The Coalition for Epidemic Preparedness Innovations (CEPI) is funding the study. CEPI has previously provided Inovio with Lassa fever related funding. In 2018, the foundation granted the company $56 million to develop vaccine candidates for Lassa fever and Middle East Respiratory Syndrome (MERS).

    A Phase 1 study has already taken place in the US, for which the candidate produced strong antibody and T cell immune responses.
  • A
    AMA33
    Posted by Lakers on IHUB. Advaccine finished 2nd dosing 640 people in China P2 trial Jan 2021, to start P3 Mar 2021. Wk6 Data submitted to National Medical Products Administration which was founded on the basis of the former State Food and Drug Administration.

    * INO-4800 is being tested against UK and S.Africa mutations, they will update INO-4800 design if needed

    * Ino is developing Pan-CoV aka multi-valent vaccine concurrently with 3rd dose booster shot trial.

    * US P3 trial to start in Q2 upon FDA approval
    * Very well tolerated, only grade 1 side effects
    * New Cellectra device is super cool, one button operated, gives visual and audio feedback when the procedure is completed, powered by alkaline or rechargeable batteries, USB port to charge the device etc.
    Looks like an average person would be able to use it after 30 min of training :)

    JK at NYAS:
    1. 5 year shelf live vs 1 year shelf life of other vaccines
    2. No need to freeze the vaccine, can handle all temperatures.
    3. 1 & 2 means easier distribution of vaccine
    4. Better immune response, T-cell response, makes the vaccine cross protective which means long term protection from Covid.
    5. Better antibody response (meaning you won’t get Covid again)
    6. Vaccine is all natural which means no allergic reaction like current vaccines with harmful PEG preservatives
    7. Animals trials have shown you only need 1 dose not multiple doses like current vaccines. This could allude to adding a new single-dose-only 2mg P3 cohort in US and China
    8. Has proven to also work on mutant strains. Most recently the newest mutation in Africa and UK. Also INO vaccine is the easiest to adjust for future mutations
    9. Department of defense funding for vaccine
    10. Plans to be #1 vaccine for second wave of Covid
    11. China Phase 2 data will be out end of this Feb month
    12. US Phase 3 data in second quarter
    13. All clinical trial percentages were very high
  • U
    Uncle
    * Advaccine finished 2nd dosing 640 people in China P2 trial Jan 2021, to start P3 Mar 2021. Wk6 Data submitted to National Medical Products Administration which was founded on the basis of the former State Food and Drug Administration.

    * INO-4800 is being tested against UK and S.Africa mutations, they will update INO-4800 design if needed

    * Ino is developing Pan-CoV aka multi-valent vaccine concurrently with 3rd dose booster shot trial.

    * US P3 trial to start in Q2 upon FDA approval
    * Very well tolerated, only grade 1 side effects
    * New Cellectra device is super cool, one button operated, gives visual and audio feedback when the procedure is completed, powered by alkaline or rechargeable batteries, USB port to charge the device etc.
    Looks like an average person would be able to use it after 30 min of training :)

    JK at NYAS:
    1. 5 year shelf live vs 1 year shelf life of other vaccines
    2. No need to freeze the vaccine, can handle all temperatures.
    3. 1 & 2 means easier distribution of vaccine
    4. Better immune response, T-cell response, makes the vaccine cross protective which means long term protection from Covid.
    5. Better antibody response (meaning you won’t get Covid again)
    6. Vaccine is all natural which means no allergic reaction like current vaccines with harmful PEG preservatives
    7. Animals trials have shown you only need 1 dose not multiple doses like current vaccines. This could allude to adding a new single-dose-only 2mg P3 cohort in US and China
    8. Has proven to also work on mutant strains. Most recently the newest mutation in Africa and UK. Also INO vaccine is the easiest to adjust for future mutations
    9. Department of defense funding for vaccine
    10. Plans to be #1 vaccine for second wave of Covid
    11. China Phase 2 data will be out end of this Feb month
    12. US Phase 3 data in second quarter
    13. All clinical trial percentages were very high

    https://drive.google.com/file/d/1K-VroKexp4TXKLAxd-8J4CaZqPda8Os8/view?usp=drivesdk
    poppy1.pdf
    drive.google.com
  • D
    Dana
    Thank you for your interest in the INOVIO’s Phase 2/3 COVID-19 clinical trial (INNOVATE). Unfortunately, this clinical trial is fully enrolled and at this time we don’t anticipate enrolling any additional subjects. Please refer to www.inovio.com for future reference.
    Sincerely,
    Clinical Trials Team at Inovio
  • C
    Common Sense
    CEPI funding 3 Inovio trials-
    https://cepi.net/research_dev/our-portfolio/
  • N
    NICK
    Important: INFLATION and STOCKS. Someone asked why higher interest rates (or fear of them) are detrimental to stocks — one of the reasons for today’s market correction. I think this explanation needed a separate post. Nothing I am saying is new or original but I hope my summary helps.

    Rising interest rates are detrimental in multiple ways - the cost to borrow money (interest) is increased for both companies and individuals by banks. Therefore, more money is spent to pay the interest — less to spend by consumers b/c of rising mortgage (unless fixed) or credit card rates (almost never fixed). New personal loans will also be more expensive.

    For companies, they will have less money to invest (and will need to spend more to pay back interest for any loan). Therefore, companies are less likely to expand and that means potentially lower profits. That’s what really scares Wall St along with reduced consumer spending which is a huge driver of the economy. For example, fewer iPhones are needed and so fewer are made and sold. Less profit.

    Also, the money a person or company earns has less value or buying power because the costs of raw materials (for a company) or finished products (for a consumer) is increased.

    Also, big institutional money flows out of the stock market when inflation is higher to get new higher-yield paying bonds as a safe haven. Thus stocks and bonds compete, in some ways, for the same big pool of institutional money.

    A small increase in interest might seem like a minor thing but the multiple effect on a trillion dollar economy is huge. Hope this helps.

    We’ll see if this is a 1 or 2 day dip on inflation fears and top-heavy valuations (share prices), or a true technical market correction. GLTAL
  • U
    Uncle
    2/25 In the fight against novel COVID-19 variants, Norway and Germany provide vital additional $169M funds to CEPI

    25 Feb 2021

    Norway, one of the co-founders of CEPI, announced this week that it will contribute US $24 million (NOK 200 million) towards CEPI’s R&D efforts to future-proof vaccines against current and future variants of the SARS-CoV-2 virus.

    The financial commitment follows the US $145 million (EUR 120 million) donation announced by the Government of Germany last week following the extraordinary G7 virtual summit to support CEPI’s COVID-19 vaccine programmes. The funding is as part of a wider US $1.82 billion (EUR 1.5 billion) donation package to partners of the Access to COVID-19 Tools (ACT) Accelerator.

    These investments come at a critical time of the COVID-19 pandemic, with CEPI seeking to expand its efforts and respond to the rapidly evolving crisis.

    The new funding will support CEPI’s goal of raising $1 billion in 2021 to carry out critical R&D to future-proof vaccines against emerging variants, maximise the available supply of vaccines, and fill in current clinical research and development gaps to optimise the use of the vaccines we have.
  • A
    Anthony
    Happy Friday to all longs, stay safe, healthy, and enjoy the weekend. I expect little of substance Monday, just a lot of “soon”. Holding long, praying this thing moves back swiftly through the teens and back to the roaring twenties. Expectations are low, as I have held score position over a year, hoping to be pleasantly surprised.
  • t
    tau72
    Here is my take about what Kim is going to tell us about INO's covid vaccine on Monday.

    1...P1/2 Korea (funded by IVI) enrollment completed. Data will be out "soon", expect to receive more funding to continue P2/3 in 2H
    2...P2 China with partner Advancine trial completed. Data will be out "soon", P3 is expected in March
    3...P2 US enrollment completed. Data will be out "in the next few weeks". INO has been actively working with FDA regarding the P3's partial hold. P3 will start as soon as FDA remove the hold (Apr - May)
  • A
    Adel
    It’s incredible the number of bashers in the board today .. we are not going to sell .. get it
  • M
    Michael - INOARMY
    INOVIO BOARD OPTIONS

    Am I reading this right? Have all the board members received their full options for the Sept 3 2020 8K filing. Wouldn’t that mean they have received FDA approval? That target is tied to 30% of the award. Can someone else check this please.
  • 5
    5000k
    so total amount Kim will receive is 319,800 share X 11.1 = $3,549,780 and total amount for the incentive is $3,500.000.

    Do I read this right??
  • l
    lead worker
    I can understand why people would not invest in INO. It might be too speculative and too volatile.
    What I can't understand is why shorts expect it to go much lower without bad news.
    If VGX-3100 flops, I might lose, although now I even have INO-4800 as a hedge.

    So far their science has shown promise of revolutionizing the world of medicine. I see risk/reward 100x greater to the upside.